Llwytho...
EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells
An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Mol Oncol |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2012
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/ https://ncbi.nlm.nih.gov/pubmed/22366308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|